Introduction
============

The increasing role of colistin in humans as a last antimicrobial resort in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae has prompted more accurate and careful monitoring of resistance to this polypeptide.[@b1-idr-11-377] To this regard, the recent emergence of the plasmid-mediated colistin resistance encoded by *mcr-1* in *Escherichia coli* has raised concern among public health experts worldwide.[@b2-idr-11-377] Due to its ability to transfer itself among bacterial strains and species by mobile genetic elements, the *mcr-1* determinant could make real the nightmare of bacterial isolates resistant to all classes of antibiotics. In line with this worrisome prospect, *mcr-1* gene has been also detected in *Klebsiella pneumoniae*, *Salmonella* spp., *Enterobacter* spp., *Citrobacter* spp., and *Shigella* spp., and sometimes associated with carbapenemase or extended-spectrum beta-lactamase (ESBL) producers.[@b1-idr-11-377],[@b3-idr-11-377]--[@b5-idr-11-377]

After its first description in People's Republic of China (2015) during the routine surveillance of food animals, the *mcr-1* gene has been reported (often retrospectively) across a wide geographic area, comprising 39 countries, in human, animal, and food-related samples.[@b4-idr-11-377],[@b6-idr-11-377] The first known MCR-1-producing isolate was from the 1980s and was detected in *E. coli* in People's Republic of China from animal source, while in humans it was isolated in 2012 from the blood.[@b7-idr-11-377],[@b8-idr-11-377] In Europe, the first MCR-1-producing strain was an *E. coli* isolated in France from animal sources in 2005.[@b9-idr-11-377] Subsequently, the *mcr-2* plasmid-mediated colistin resistance gene was detected from porcine and bovine *E. coli* in Belgium,[@b10-idr-11-377] and a variant of the *mcr-1* determinant (named *mcr-1.2*) was isolated from the rectal swab of an Italian child in *K. pneumoniae*.[@b11-idr-11-377] A third mobile colistin resistance gene, *mcr-3*, has been reported in *E. coli*, *Aeromonas* spp., and *Salmonella* spp. isolates from human and animal samples,[@b12-idr-11-377]--[@b16-idr-11-377] whereas the *mcr-4* and *mcr-5* genes were detected in *Salmonella* spp. and *E. coli* isolates, but only from animal sources.[@b17-idr-11-377]--[@b19-idr-11-377] In summary, plasmid-mediated resistance to colistin had been around for more than 25 years, but without being detected until 2015.

The history of plasmid-mediated resistance to colistin had a very important veterinary component. Although colistin has been used in clinical settings in a limited manner in the past, due to its nephrotoxicity, its use in veterinary medicine has been carried on for decades (as it was so far a cheap antibiotic).[@b1-idr-11-377],[@b20-idr-11-377] The main indications for colistin use in veterinary setting are the prevention and treatment of infections caused by Enterobacteriaceae (especially gastrointestinal disorders), but it has been used as growth promoter in terrestrial and aquatic animals.[@b20-idr-11-377],[@b21-idr-11-377] Data regarding colistin resistance in bacteria from animals and food of animal origin are relatively scarce. Prevalence of colistin resistance in *E. coli* from animals (pigs, ruminants, poultries, and companion animals) shows wide differences ranging from 0% to 52.4%, with highest resistance percentages reported from Asia.[@b20-idr-11-377] It has been reported in several studies that the *E. coli* colistin resistance rate is higher in pigs compared with other animal productions.[@b6-idr-11-377],[@b21-idr-11-377]--[@b23-idr-11-377] Not all studies recognized the colistin resistance mechanism, and so the real prevalence of *mcr-1* determinant in the veterinary setting remains still largely underestimated.[@b20-idr-11-377] In this scenario, due to the high rate of colistin-resistant (CR) *E. coli* carrying the *mcr-1* gene isolated from food animals compared with humans, livestock production was pinpointed as the greatest cause of colistin resistance amplification and spread, also in humans.[@b6-idr-11-377],[@b21-idr-11-377] This source of infection led to consider MCR-1-producing *E. coli* mostly as a community-associated microorganism, being isolated especially in outpatient samples. In this context, several publications have reported the detection of CR *E. coli* from healthy individuals without prior colistin usage.[@b21-idr-11-377],[@b24-idr-11-377]--[@b27-idr-11-377] The observation of colistin resistance in humans without prior colistin exposure is of particular clinical importance and concern, because an antimicrobial stewardship program based on preservation of colistin in the hospital context could not be enough. However, *mcr-1*-positive *E. coli* has been almost never associated to hospital epidemic events, giving the reason to think to multi-variegate source of infection outside the hospital setting.

In Italy, data regarding the diffusion of *E. coli* clinical isolates harboring plasmid-mediated resistance to colistin are very scarce. The *mcr-1* determinant was firstly described in 2016 in eight *E. coli* isolates collected from clinical specimens during the period 2013--2015 in two hospitals.[@b28-idr-11-377] Later, another study reported the presence of three *E. coli* isolates producing both MCR-1 and CTX-M-type ESBL enzymes as intestinal carriage in long-term care facilities residents, during a point prevalence survey on ESBL-producing Enterobacteriaceae.[@b29-idr-11-377] More recently, three cases of bloodstream infections caused by MCR-1-producing *E. coli* were reported among oncologic patients,[@b30-idr-11-377] whereas 37 out of 51 (72.5%) CR *E. coli* isolates from pigs were positive for *mcr-1* gene.[@b31-idr-11-377] Finally, the *mcr-1* determinant was detected in *S. enterica* isolates obtained from human and animals in the period 2012--2015,[@b32-idr-11-377] and the more recent *mcr-4* gene was detected in *S. enterica* serovar Typhimurium (collected in 2013 and retrospectively studied) from an animal source.[@b17-idr-11-377] The aim of our study was to investigate 1) the prevalence of this resistance trait in *E. coli* isolates from clinical samples, 2) the presence of *mcr*-type genes, and 3) their genetic relationship. Our work represents the first evaluation of the diffusion of clinical *mcr*-1-positive *E. coli* in a specific defined area in our country.

Materials and methods
=====================

Study design and participating centers
--------------------------------------

Bacterial isolates were obtained during a multicenter prospective study that involved six clinical microbiology laboratories located in the Lombardy region (Northern Italy). The following centers were included: Busto Arsizio, Lecco, Legnano, Lodi, Rozzano, and Vimercate ([Figure 1](#f1-idr-11-377){ref-type="fig"}). Participating hospitals had approximately 4,000 beds and served 2,400,000 people. The survey was conducted over a 4-month period, starting in May 2016. Consecutive nonduplicate clinical isolates of *E. coli* from any type of clinical specimen, with the exception of rectal swabs, were included in the study. Isolates that exhibited MIC values for colistin \>2 mg/L were further investigated. Bacterial identification and antimicrobial susceptibility testing were routinely carried out by the collecting laboratories using either the Phoenix automated system (Becton Dickinson Diagnostic Systems, Sparks, MD, USA) or the Vitek2 system (bioMérieux, Marcy l'Etoile, France). Both inpatients and outpatients were included in the study. Outpatients were defined as patients not hospitalized at the time of specimen collection. For each isolate, information on the clinical specimen and type of ward (in the case of isolates from inpatients) was included. Moreover, each participating laboratory provided information on the total number of consecutive nonduplicate clinical isolates of *E. coli* observed during the collection period. The collected isolates were sent to reference laboratories for confirmation of both species identification and antimicrobial resistance. Characterization of the colistin resistance mechanism(s) and analysis of clonal relatedness were also carried out.

Characterization of bacterial isolates
--------------------------------------

Bacterial identification of collected isolates was assessed by matrix-assisted laser desorption ionization-time of flight mass spectrometry (Vitek MS; bioMérieux). Antimicrobial susceptibility for colistin was evaluated by the reference broth microdilution method using a dedicated TREK panel (DKMGN; Thermo Fisher Diagnostics, Milan, Italy). This panel also provided MIC values for amoxicillin-clavulanate, piperacillin-tazobactam, cefotaxime, ceftazidime, aztreonam, ertapenem, imipenem, meropenem, ciprofloxacin, amikacin, gentamicin, tobramycin, trimethoprim-sulfamethoxazole, ceftolozane-tazobactam, ceftazidime-avibactam, and tigecycline. All collected isolates confirmed to be resistant to colistin according to EUCAST breakpoints[@b33-idr-11-377] (MIC value \>2 mg/L) were evaluated for the presence of *mcr*-type genes.

Characterization of antimicrobial resistance determinants
---------------------------------------------------------

The presence of the *mcr*-type determinants (−1 to −5 variants) was investigated by PCR using specific primers and conditions, as previously described.[@b6-idr-11-377],[@b10-idr-11-377],[@b12-idr-11-377],[@b17-idr-11-377],[@b18-idr-11-377]

The content of the entire beta-lactamase resistance determinants of the *mcr*-type-positive isolates was tested by the Check-MDR CT103XL array (Check-Points Health B.V., Wageningen, The Netherlands).

Molecular typing
----------------

Repetitive sequence-based PCR (rep-PCR) was performed with the Diversilab (DL) System (bioMérieux), according to the manufacturer's instructions. DNA extraction was performed with the UltraClean Microbial DNA isolation kit (Mo Bio Laboratories Inc). Analysis of the PCR amplicons was performed using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). DL fingerprints were analyzed with the DL software 3.4, using the Pearson correlation statistical method to determine clonal relationships.

Multilocus sequence typing (MLST) of *mcr-1*-positive *E. coli* isolates was carried out according to the protocol of Wirth et al. (2006).[@b34-idr-11-377] Allelic profiling and sequence-type (ST) determination were performed using the *E. coli* MLST scheme from the website of the University of Warwick (<http://mlst.warwick.ac.uk/mlst/dbs/Ecoli>). Phylogenetic groups were determined by a 2-step triplex PCR as described by Clermont et al.[@b35-idr-11-377]

Plasmid incompatibility groups of *mcr*-1-positive strains were determined by the PCR-based replicon typing (PBRT) method using the commercially available PBRT kit (Diatheva),[@b36-idr-11-377] according to the manufacturer's instructions. Specific primers and protocol were used for the amplification of IncX4 replicon.[@b37-idr-11-377]

Ethics approval and consent to participate
------------------------------------------

Ethics approval and consent to participate were not required. Samples were taken from six different institutions as part of the standard patient care and used anonymously.

Results
=======

Bacterial isolates and epidemiological data
-------------------------------------------

A total of 3,902 consecutive nonduplicate *E. coli* clinical isolates (outpatients, n=2,342; inpatients, n=1,560) were evaluated during the collection period. Of note, *E. coli* isolates obtained from patients admitted to nursing homes (included in the outpatients group) accounted for 5.8% (n=135) of study isolates. Clinical isolates were mostly obtained from urine samples (n=3070, 78.7%), followed by skin and soft tissues (n=316, 8.1%), and blood cultures (n=301, 7.7%).

Overall, 18 out of 3,902 (0.5%) isolates, collected from 4/6 centers, were confirmed as CR (MIC\>2 mg/L). In particular, 6/18 were from inpatients and 12/18 from outpatients (no one from nursing homes). Thus, the prevalence of colistin resistance was 0.5% (6/1560) and 0.4% (12/2342) among inpatients and outpatients, respectively. Particularly, CR isolates recovered from hospitalized patients came from medical (n=3), rehabilitation (n=2), and surgical (n=1) wards. Overall, CR isolates were obtained from patients (male, n=8; female, n=10) aging from 52 to 94 years, mostly from urine samples (n=16), while the remaining isolates were from blood cultures (n=2).

Molecular characterization and genetic relationship among *mcr-1*-positive *E. coli* clinical isolates
------------------------------------------------------------------------------------------------------

PCR analysis detected the *mcr-1* gene in 10/18 CR isolates, all of which were from urine samples (seven from outpatients and three from inpatients). Isolates were uniformly negative for other *mcr*-type genes. Genetic relationship among *mcr-1*-positive isolates was investigated using different methods. The Rep-PCR technique showed the presence of nine different clusters (data not shown). These data agreed with MLST analysis that revealed nine different STs, with a new one consisting of the following allelic profile: 6--23--5--8--24--18--6. The phylogenetic group analysis showed high heterogeneity among isolates: four belonged to groups A and D, respectively, whereas the remaining two strains were from groups B1 and B2. Seven *mcr-1*-positive isolates harbored a plasmid of IncX4 group; in three cases, the IncHI2 incompatibility group was found. Details are reported in [Table 1](#t1-idr-11-377){ref-type="table"}.

Antimicrobial susceptibility of CR isolates and associated resistance mechanisms
--------------------------------------------------------------------------------

As shown in [Table 2](#t2-idr-11-377){ref-type="table"}, *mcr-1*-positive isolates showed MIC values for colistin ranging from 4 to 8 mg/L. These isolates were frequently resistant to co-trimoxazole (8/10) and ciprofloxacin (8/10), and sometimes also to gentamicin (3/10) and tobramycin (3/10). Notably, two of them (both positive for the SHV-12 determinant) were not susceptible to third-generation cephalosporins (cefotaxime and ceftazidime). In all cases, however, carbapenems (ertapenem, imipenem, and meropenem), amikacin, ceftazidime/avibactam, ceftolozane/tazobactam, and tigecycline maintained their activity. As assessed by microarray analysis, six isolates co-harbored the *bla*~TEM-1~ gene ([Table 1](#t1-idr-11-377){ref-type="table"}).

Similarly to *mcr-1*-positive isolates, *mcr*-type-negative isolates had MIC values for colistin ranging from 4 to 8 mg/L ([Table 3](#t3-idr-11-377){ref-type="table"}). With the exception of ciprofloxacin (4/8 isolates), resistance to other antimicrobials was overall rare, even though three of them were not susceptible to third-generation cephalosporins (cefotaxime and ceftazidime) due to ESBL production.

Discussion
==========

Colistin is increasingly used as one of the last available treatment options for patients with severe infections caused by carbapenem-resistant Enterobacteriaceae, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa*.[@b2-idr-11-377],[@b38-idr-11-377] Colistin resistance follows the increasing trend in consumption of colistin in human medicine, especially in countries with high rates of carbapenem-resistant gram-negative bacilli, including Italy.[@b39-idr-11-377] Chromosomally mediated resistance, often generated by mutations in the *mgrB* gene and upregulation of *PhoP*/*PhoQ* system, seems to be related to this trend and mostly associated with *K. pneumoniae* in the hospital setting.[@b40-idr-11-377]--[@b43-idr-11-377] A mutation in the *pmrB* gene has been also recently described in *E. coli*.[@b44-idr-11-377] On the contrary, the plasmid-mediated colistin resistance (mostly due to the *mcr-1* determinant) has been especially found in *E. coli*, a common cause of urinary tract infections in healthy individuals in the community setting without prior colistin usage.[@b21-idr-11-377],[@b24-idr-11-377]--[@b27-idr-11-377]

Prevalence data on colistin resistance are overall scarce. In particular, data regarding the plasmid-mediated resistance to colistin among clinical isolates of *E. coli* are lacking in Italy. This prospective multicenter study represents the first evaluation on the dissemination of clinical isolates of *mcr-1*-positive *E. coli* in Lombardy, the most inhabited Italian region, accounting for about 10 million of residents. Our results show that resistance to colistin in *E. coli* clinical isolates is almost low in this area (0.5%), with similar percentages among both inpatients and outpatients (0.5% and 0.4%, respectively). Notably, considering only outpatients, resistance to colistin was not detected in nursing home patients, thus enforcing the theory of a major risk source outside the health-care setting.[@b1-idr-11-377],[@b3-idr-11-377],[@b4-idr-11-377],[@b20-idr-11-377],[@b21-idr-11-377],[@b24-idr-11-377],[@b38-idr-11-377]

As a limitation of the study, however, it should be taken into account that some methodological difficulties affect automated systems in determining the correct MIC value for colistin, especially when it ranges from 1 to 2 mg/L. This issue could lead to a possible underestimation of colistin resistance.

With regard to *mcr-1*-positive isolates, they accounted for approximately 50% of CR *E. coli* isolates, thus representing a relevant mechanism in the context of colistin resistance. Overall, however, these isolates represented a low rate (10 isolates, 0.2%) of total isolates studied in the survey. These results are similar to the previously published prevalence data, ranging from 0.05% to 1%.[@b6-idr-11-377],[@b45-idr-11-377]--[@b52-idr-11-377] The aforementioned studies included isolates from infected or colonized patients and showed higher prevalence rates in Asian countries compared with those reported from Europe, thus highlighting a major concern toward *mcr*-related colistin resistance in that geographic area. This issue is reinforced by a high prevalence value of 3.5% described in a report including colonized patients from People's Republic of China.[@b53-idr-11-377]

These data, showing a low prevalence of *mcr-1*-positive isolates, are mostly reassuring since *mcr-1* appears as a transferable resistance determinant capable of limited propensity to spread so far. To date, it was never associated with epidemic events, even though association of *mcr*-type determinants with high-risk clones (e.g., *E. coli* ST131) capable of large diffusion has been described.[@b16-idr-11-377],[@b28-idr-11-377] Moreover, other resistance determinants (including those responsible for carbapenemase and ESBL production) have been already reported in association with *mcr* genes, mainly limiting therapeutic options really effective against these strains.[@b54-idr-11-377],[@b55-idr-11-377]

As previously reported, *mcr-1*-positive isolates usually show a multi-susceptible profile.[@b1-idr-11-377],[@b6-idr-11-377],[@b28-idr-11-377] In our study, resistance to co-trimoxazole (8/10 isolates) and ciprofloxacin (8/10 isolates) was common. Interestingly, *mcr-1*-positive isolates were detected only in urine samples. Furthermore, 2/10 isolates were resistant to third-generation cephalosporins (cefotaxime and ceftazidime) due to ESBL production. This worrisome finding could essentially reflect Italian epidemiology for ESBL production in *E. coli* isolates circulating among both inpatients and outpatients.[@b56-idr-11-377]

All *mcr-1*-positive isolates were genetically unrelated, as demonstrated by molecular typing. Both Rep-PCR and MLST revealed nine different clusters, giving the reason to assess a multi-variegate source of infection. Only one couple of isolates was genetically related despite these isolates had been collected from different centers and had no obvious epidemiological link.

In conclusion, we can speculate that the prevalence of CR *E. coli* isolates is low in our region, and the diffusion of *mcr-1* determinant is very limited among clinical isolates. No epidemic events caused by CR *E. coli* are so far described in Italy in the hospital setting, thus highlighting the community origin of these isolates. Accordingly, in our experience, *mcr-1*-positive strains were not genetically related and were mostly isolated from outpatients, evidencing their different sources and the low-level diffusion in the community. Although limited, the presence of *mcr-1* determinant in our region should not be ignored. Great concern should be given to continuous surveillance, improving prevalence data in both human and veterinary settings in our country.
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###### 

Characteristics of *mcr-1*-positive *E. coli* clinical isolates

  Center      Strain code   Date of isolation   Patient data (sex, age \[years\])   Hospital service/per ward   Colistin MIC value (mg/L)   Other BL resistance determinants   ESBL profile   Sequence type   Rep-PCR profile   Inc-type   Phylogroup
  ----------- ------------- ------------------- ----------------------------------- --------------------------- --------------------------- ---------------------------------- -------------- --------------- ----------------- ---------- ------------
  Busto A.    01-EC01       Oct. 2016           M, 65                               Outpatient                  4                           --                                 Neg            ST354           1                 IncX4      D
  Lecco       02-EC08       Aug. 2016           M, 52                               Rehabilitation              8                           TEM-1                              Neg            ST617           6                 IncX4      A
  Lecco       02-EC09       Aug. 2016           F, 87                               General surgery             4                           TEM-1                              Neg            ST93            8                 IncHI2     A
  Lodi        04-EC16       Jun. 2016           M, 83                               Outpatient                  4                           TEM-1, SHV-12                      Pos            ST88            2                 IncX4      A
  Lodi        04-EC17       Jun. 2016           F, 83                               Outpatient                  8                           TEM-1                              Neg            ST428           3                 IncHI2     B2
  Lodi        04-EC18       Jul. 2016           F, 94                               Rehabilitation              8                           TEM-1                              Neg            ST117           5                 IncHI2     D
  Lodi        04-EC21       Aug. 2016           M, 74                               Outpatient                  4                           --                                 Neg            new ST          7                 IncX4      A
  Lodi        04-EC22       Aug. 2016           M, 77                               Outpatient                  8                           TEM-1                              Neg            ST359           9                 IncX4      B1
  Vimercate   06-EC05       Jun. 2016           F, 77                               Outpatient                  4                           SHV-12                             Pos            ST69            4                 IncX4      D
  Vimercate   06-EC07       Aug. 2016           F, 73                               Outpatient                  8                           --                                 Neg            ST117           5                 IncX4      D

**Abbreviations:** BL, beta-lactam; ESBL, extended-spectrum beta-lactamase; F, female; M, male; Neg, negative; Pos, positive; Rep-PCR, repetitive sequence-based PCR; ST, sequence type; Aug, August; Jun, June; Oct, October.

###### 

Susceptibility profile of *mcr-1*-positive *E. coli* clinical isolates, as assessed by broth microdilution method

  Strain code   AMC      TZP      AZT     CTX     CAZ     CFT      CZA      ERT      IMP     MEM      CIP     SXT       AMK     GEN     TOB     TIG     COL
  ------------- -------- -------- ------- ------- ------- -------- -------- -------- ------- -------- ------- --------- ------- ------- ------- ------- -----
  01-EC01       ≤4/2     ≤1/4     ≤0.5    ≤0.5    ≤0.5    ≤0.5/4   ≤0.5/4   ≤0.125   ≤0.5    ≤0.125   \>2     \>8/152   ≤4      \>8     8       ≤0.25   4
  \(S\)         \(S\)    \(S\)    \(S\)   \(S\)   \(S\)   \(S\)    \(S\)    \(S\)    \(S\)   \(R\)    \(R\)   \(S\)     \(R\)   \(R\)   \(S\)   \(R\)   
  02-EC08       8/2      8/4      ≤0.5    ≤0.5    ≤0.5    ≤0.5/4   ≤0.5/4   ≤0.125   ≤0.5    ≤0.125   \>2     ≤1/19     ≤4      1       ≤1      ≤0.25   8
  \(S\)         \(S\)    \(S\)    \(S\)   \(S\)   \(S\)   \(S\)    \(S\)    \(S\)    \(S\)   \(R\)    \(S\)   \(S\)     \(S\)   \(S\)   \(S\)   \(R\)   
  02-EC09       8/2      ≤1/4     ≤0.5    ≤0.5    ≤0.5    ≤0.5/4   ≤0.5/4   ≤0.125   ≤0.5    ≤0.125   1       \>8/152   ≤4      ≤0.5    ≤1      ≤0.25   4
  \(S\)         \(S\)    \(S\)    \(S\)   \(S\)   \(S\)   \(S\)    \(S\)    \(S\)    \(S\)   \(R\)    \(R\)   \(S\)     \(S\)   \(S\)   \(S\)   \(R\)   
  04-EC16       \>64/2   \>32/4   \>32    2       \>16    ≤0.5/4   ≤0.5/4   ≤0.125   ≤0.5    ≤0.125   \>2     \>8/152   ≤4      8       8       ≤0.25   4
  \(R\)         \(R\)    \(R\)    \(I\)   \(R\)   \(S\)   \(S\)    \(S\)    \(S\)    \(S\)   \(R\)    \(R\)   \(S\)     \(R\)   \(R\)   \(S\)   \(R\)   
  04-EC17       8/2      ≤1/4     ≤0.5    ≤0.5    ≤0.5    ≤0.5/4   ≤0.5/4   ≤0.125   ≤0.5    ≤0.125   0,25    \>8/152   ≤4      ≤0.5    ≤1      ≤0.25   8
  \(S\)         \(S\)    \(S\)    \(S\)   \(S\)   \(S\)   \(S\)    \(S\)    \(S\)    \(S\)   \(S\)    \(R\)   \(S\)     \(S\)   \(S\)   \(S\)   \(R\)   
  04-EC18       \>64/2   4/4      ≤0.5    ≤0.5    ≤0.5    ≤0.5/4   ≤0.5/4   ≤0.125   ≤0.5    ≤0.125   \>2     \>8/152   ≤4      1       ≤1      ≤0.25   8
  \(R\)         \(S\)    \(S\)    \(S\)   \(S\)   \(S\)   \(S\)    \(S\)    \(S\)    \(S\)   \(R\)    \(R\)   \(S\)     \(S\)   \(S\)   \(S\)   \(R\)   
  04-EC21       32/2     2/4      ≤0.5    ≤0.5    ≤0.5    ≤0.5/4   ≤0.5/4   ≤0.125   ≤0.5    ≤0.125   ≥2      \>8/152   ≤4      ≤0.5    ≤1      ≤0.25   4
  \(S\)         \(S\)    \(S\)    \(S\)   \(S\)   \(S\)   \(S\)    \(S\)    \(S\)    \(S\)   \(R\)    \(R\)   \(S\)     \(S\)   \(S\)   \(S\)   \(R\)   
  04-EC22       16/2     ≤1/4     ≤0.5    ≤0.5    ≤0.5    ≤0.5/4   ≤0.5/4   ≤0.125   ≤0.5    ≤0.125   ≥2      \>8/152   ≤4      \>8     8       ≤0.25   8
  \(S\)         \(S\)    \(S\)    \(S\)   \(S\)   \(S\)   \(S\)    \(S\)    \(S\)    \(S\)   \(R\)    \(R\)   \(S\)     \(R\)   \(R\)   \(S\)   \(R\)   
  06-EC05       8/2      ≤1/4     16      \>8     4       ≤0.5/4   ≤0.5/4   ≤0.125   ≤0.5    ≤0.125   0,25    \>8/152   ≤4      ≤0.5    ≤1      ≤0.25   4
  \(S\)         \(S\)    \(R\)    \(R\)   \(I\)   \(S\)   \(S\)    \(S\)    \(S\)    \(S\)   \(S\)    \(R\)   \(S\)     \(S\)   \(S\)   \(S\)   \(R\)   
  06-EC07       ≤4/2     2/4      ≤0.5    ≤0.5    ≤0.5    ≤0.5/4   ≤0.5/4   ≤0.125   ≤0.5    ≤0.125   ≥2      ≤1/19     ≤4      ≤0.5    ≤1      ≤0.25   8
  \(S\)         \(S\)    \(S\)    \(S\)   \(S\)   \(S\)   \(S\)    \(S\)    \(S\)    \(S\)   \(R\)    \(S\)   \(S\)     \(S\)   \(S\)   \(S\)   \(R\)   

**Abbreviations:** AMC, amoxicillin-clavulanate; AMK, amikacin; AZT, aztreonam; CAZ, ceftazidime; CFT, ceftolozane-tazobactam; CIP, ciprofloxacin; COL, colistin; CTX, cefotaxime; CZA, ceftazidime-avibactam; *E. coli*, *Escherichia coli*; ERT, ertapenem; GEN, gentamicin; IMP, imipenem; MEM, meropenem; SXT, trimethoprim-sulfamethoxazole; TIG, tigecycline; TOB, tobramycin; TZP, piperacillin-tazobactam; S, susceptible; R, resistant.

###### 

Susceptibility profile of *mcr*-type-negative *E. coli* clinical isolates, as assessed by broth microdilution method

  Strain code   AZT     AMC     TZP     CTX     CAZ     CFT      CZA      ERT      IMP     MEM      CIP     SXT       AMK     GEN     TOB     TIG     COL
  ------------- ------- ------- ------- ------- ------- -------- -------- -------- ------- -------- ------- --------- ------- ------- ------- ------- -----
  02-EC05       ≤0.5    ≤4/2    ≤1/4    ≤0.5    ≤0.5    ≤0.5/4   ≤0.5/4   ≤0.125   ≤0.5    ≤0.125   ≤0.06   ≤1/19     ≤4      ≤0.5    ≤1      ≤0.25   4
  \(S\)         \(S\)   \(S\)   \(S\)   \(S\)   \(S\)   \(S\)    \(S\)    \(S\)    \(S\)   \(S\)    \(S\)   \(S\)     \(S\)   \(S\)   \(S\)   \(R\)   
  02-EC06       ≤0.5    ≤4/2    ≤1/4    ≤0.5    ≤0.5    ≤0.5/4   ≤0.5/4   ≤0.125   ≤0.5    ≤0.125   ≤0.06   ≤1/19     ≤4      ≤0.5    ≤1      ≤0.25   8
  \(S\)         \(S\)   \(S\)   \(S\)   \(S\)   \(S\)   \(S\)    \(S\)    \(S\)    \(S\)   \(S\)    \(S\)   \(S\)     \(S\)   \(S\)   \(S\)   \(R\)   
  04-EC10       ≤0.5    32/2    ≤1/4    ≤0.5    ≤0.5    ≤0.5/4   ≤0.5/4   ≤0.125   ≤0.5    ≤0.125   \>2     ≤1/19     ≤4      ≤0.5    ≤1      ≤0.25   4
  \(S\)         \(S\)   \(S\)   \(S\)   \(S\)   \(S\)   \(S\)    \(S\)    \(S\)    \(S\)   \(R\)    \(S\)   \(S\)     \(S\)   \(S\)   \(S\)   \(R\)   
  04-EC19       \>32    64/2    2/4     \>8     \>16    1/4      ≤0.5/4   ≤0.125   ≤0.5    ≤0,125   \>2     \>8/152   ≤4      ≤0.5    ≤1      ≤0.25   8
  \(R\)         \(R\)   \(S\)   \(R\)   \(R\)   \(S\)   \(S\)    \(S\)    \(S\)    \(S\)   \(R\)    \(R\)   \(S\)     \(S\)   \(S\)   \(S\)   \(R\)   
  04-EC20       ≤0.5    ≤4/2    ≤1/4    ≤0.5    ≤0.5    ≤0.5/4   ≤0.5/4   ≤0.125   ≤0.5    ≤0,125   ≤0.06   ≤1/19     ≤4      ≤0.5    ≤1      ≤0.25   8
  \(S\)         \(S\)   \(S\)   \(S\)   \(S\)   \(S\)   \(S\)    \(S\)    \(S\)    \(S\)   \(S\)    \(S\)   \(S\)     \(S\)   \(S\)   \(S\)   \(R\)   
  04-EC23       16      32/2    ≤1/4    \>8     8       ≤0.5/4   ≤0.5/4   ≤0.125   ≤0.5    ≤0.125   \>2     ≤1/19     ≤4      ≤0.5    ≤1      ≤0.25   4
  \(R\)         \(S\)   \(S\)   \(R\)   \(R\)   \(S\)   \(S\)    \(S\)    \(S\)    \(S\)   \(R\)    \(S\)   \(S\)     \(S\)   \(S\)   \(S\)   \(R\)   
  04-EC24       16      32/2    ≤1/4    \>8     4       ≤0.5/4   ≤0.5/4   ≤0.125   ≤0.5    ≤0.125   \>2     ≤1/19     ≤4      ≤0.5    ≤1      ≤0.25   4
  \(R\)         \(S\)   \(S\)   \(R\)   \(I\)   \(S\)   \(S\)    \(S\)    \(S\)    \(S\)   \(R\)    \(S\)   \(S\)     \(S\)   \(S\)   \(S\)   \(R\)   
  06-EC06       ≤0.5    ≤4/2    ≤1/4    ≤0.5    ≤0.5    ≤0.5/4   ≤0.5/4   ≤0.125   ≤0.5    ≤0.125   ≤0.06   ≤1/19     ≤4      ≤0.5    ≤1      ≤0.25   4
  \(S\)         \(S\)   \(S\)   \(S\)   \(S\)   \(S\)   \(S\)    \(S\)    \(S\)    \(S\)   \(S\)    \(S\)   \(S\)     \(S\)   \(S\)   \(S\)   \(R\)   

**Abbreviations:** AMC, amoxicillin-clavulanate; AMK, amikacin; AZT, aztreonam; CAZ, ceftazidime; CFT, ceftolozane-tazobactam; CIP, ciprofloxacin; COL, colistin; CTX, cefotaxime; CZA, ceftazidime-avibactam; *E. coli*, *Escherichia coli*; ERT, ertapenem; GEN, gentamicin; IMP, imipenem; MEM, meropenem; SXT, trimethoprim-sulfamethoxazole; TIG, tigecycline; TOB, tobramycin; TZP, piperacillin-tazobactam; S, susceptible; R, resistant.
